What was studied?
Patient biomarker observations were combined with mouse receptor-knockout experiments and human endothelial-cell assays.
What did the researchers report?
Lower circulating levels were observed in patients; experimentally administered peptide reduced selected aneurysm-related findings in wild-type mice but not receptor-deficient mice.
What are the limits?
The human component was observational and the intervention evidence was preclinical. These two parts cannot be combined into a claim that the peptide prevents human aneurysms.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.